Form 4 for MIRM Mirum Pharmaceuticals, Inc.
Accepted 2026-08-11 17:41:43 ET · period of report 2026-08-10 · accession 0001614740-26-000012 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-08-11 17:41 | 2026-08-10 | MIRM | Peetz Christopher | CEO, Dir | M - OptEx | $2.94 | +20.0K | 214.3K | +10% | +$58.7K |
| DMT | 2026-08-11 17:41 | 2026-08-10 | MIRM | Peetz Christopher | CEO, Dir | S - Sale+OE | $98.92 | -20.0K | 194.3K | -9% | -$1.98M |
| DT | 2026-08-11 17:41 | 2026-08-10 | MIRM | Peetz Christopher | CEO, Dir | M - OptEx | $0.00 | -20.0K | 88.5K | -18% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-10 | M | A | 20,000 | $2.94 | 214,309 | D | — | — | |
| 2 | Common | Common Stock | 2026-08-10 | S | D | 11,683 | $98.51 | 202,626 | D | — | — | (F1) Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 2, 2026. (F2) The weighted average sale price for the transaction reported was $98.51, and the range of prices were between $97.93 and $98.92. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 3 | Common | Common Stock | 2026-08-10 | S | D | 6,017 | $99.25 | 196,609 | D | — | — | (F1) Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 2, 2026. (F3) The weighted average sale price for the transaction reported was $99.25, and the range of prices were between $98.94 and $99.655. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 4 | Common | Common Stock | 2026-08-10 | S | D | 2,300 | $100.14 | 194,309 | D | — | — | (F1) Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on March 2, 2026. (F4) The weighted average sale price for the transaction reported was $100.14, and the range of prices were between $99.995 and $100.2425. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 5 | Derivative | Employee Stock Option (right to buy) | 2026-08-10 | M | D | 20,000 | $0.00 | 88,487 | D | $2.94 · — to 2029-03-11 | 20,000 Common Stock | (F5) The stock option is fully vested. |